Physician profile
Daniel Kaitis
NPI 1093208407
$3,783.94
in general payments reported to CMS, 2019-2025
14 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.58 · 2021: $2,196 · 2022: $647 · 2023: $231 · 2024: $397 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,757.97 | 2021 | |
| Alcon Vision LLC | $861.63 | 2020-2025 | Clareon |
| Bausch & Lomb Americas INC. | $219.86 | 2022-2024 | Envista Mx60 Iol |
| Regeneron Healthcare Solutions, INC. | $215.61 | 2020-2023 | Eylea |
| Sight Sciences, INC. | $138.74 | 2022-2025 | Sion Surgical Instrument, Omni Surgical System |
| Amgen INC. | $120.89 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $109.09 | 2023 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Eyepoint US, INC. | $106.24 | 2022 | |
| Harrow Eye, LLC | $76.77 | 2024-2025 | Vevye |
| New World Medical,INC. | $58.54 | 2023 | |
| Novartis Pharmaceuticals Corporation | $50.05 | 2023 | |
| Apellis Pharmaceuticals, INC. | $30.73 | 2025 | Syfovre |
| Biotissue Holdings INC. | $23.51 | 2022 | |
| Allergan, INC. | $14.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kaitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.